Pharma CEOs present united front - except on biosimilars

Seven pharma leaders expressed strong support for eliminating rebates to PBMs and insurance companies, shifting from volume- to value-based reimbursement, and reducing out-of-pocket costs for drugs in testimony Tuesday to the Senate Finance Committee.

The committee heard from Richard Gonzalez, chairman and CEO of AbbVie Inc. (NYSE:ABBV); Pascal Soriot, executive director and CEO of AstraZeneca plc (LSE:AZN; NYSE:AZN); Giovanni Caforio, chairman and CEO of Bristol-Myers Squibb Co. (NYSE:BMY); Jennifer Taubert, EVP and worldwide chairman of Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceuticals Inc.;

Read the full 823 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE